Bellerophon Therapeutics (NASDAQ:BLPH) Releases Earnings Results, Misses Expectations By $0.04 EPS

Bellerophon Therapeutics (NASDAQ:BLPHGet Rating) announced its quarterly earnings results on Wednesday. The biotechnology company reported ($0.59) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.04), MarketWatch Earnings reports.

Shares of NASDAQ BLPH traded up $0.02 during trading hours on Thursday, hitting $0.87. The company had a trading volume of 17,987 shares, compared to its average volume of 58,331. The stock has a market capitalization of $8.30 million, a P/E ratio of -0.47 and a beta of -0.17. Bellerophon Therapeutics has a 1-year low of $0.67 and a 1-year high of $5.95. The firm’s 50 day moving average is $1.89 and its 200-day moving average is $2.52.

An institutional investor recently bought a new position in Bellerophon Therapeutics stock. Millennium Management LLC acquired a new stake in Bellerophon Therapeutics, Inc. (NASDAQ:BLPHGet Rating) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 24,134 shares of the biotechnology company’s stock, valued at approximately $75,000. Millennium Management LLC owned about 0.25% of Bellerophon Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 12.93% of the company’s stock.

A number of brokerages have recently commented on BLPH. Brookline Capital Management lowered their price target on Bellerophon Therapeutics from $26.00 to $19.00 in a research note on Monday, April 4th. StockNews.com initiated coverage on Bellerophon Therapeutics in a research note on Thursday, May 5th. They set a “sell” rating for the company. Brookline Capital Acquisition lowered their target price on Bellerophon Therapeutics from $26.00 to $19.00 in a research note on Monday, April 4th. Finally, Zacks Investment Research downgraded Bellerophon Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, January 19th.

Bellerophon Therapeutics Company Profile (Get Rating)

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.

Read More

Earnings History for Bellerophon Therapeutics (NASDAQ:BLPH)

Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.